Gilead Sciences (GILD) call put ratio 1 call to 1 put, FT says remdesivir failed in first trial
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $150.11 -0.52%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: -14.2%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: -14.2%
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) call put ratio 1 call to 1 put, FT says remdesivir failed in first trial
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead expands lenacapavir licensing to cover once-yearly HIV prevention
- Pinduoduo (PDD) call put ratio 5.4 calls to 1 put into President Donald Trump and Chinese President Xi Jinping's summit
- Increasing unusual call option volume: LYTE SOLZ KHC SDGR TRMD RITM CYPH FPS DFDV SES ASST COHX
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
